The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
CONCLUSION: Nivolumab plus ipilimumab represent the most promising immunotherapy combination for the treatment of advanced NSCLC patients; safety, tolerability and efficacy of new immune modulators (in monotherapy and in immune combinations) must be further assessed in future studies.
PMID: 31400270 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Rocco D, Gravara LD, Gridelli C Tags: Curr Clin Pharmacol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Yervoy